1. U.S. Department of Health and Human Services. 10th Special Report to the US Congress on Alcohol and Health. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2000.
2. McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689–95. [PubMed] 3. Swift RM. Drug therapy for alcohol dependence. N Engl J Med. 1999;340:1482–90. [PubMed] 4. Finney JW, Hahn AC, Moos RH. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction. 1996;91:1773–96. [PubMed] 5. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals. Arch Gen Psychiatry. 2004;61:905–12. [PubMed]
6. Johnson BA, DiClemente CC, Ait-Daoud N, Stoks SM. Brief Behavioral Compliance Enhancement Treatment (BBCET) manual. In: Johnson BA, Ruiz P, Galanter M, editors. Handbook of clinical alcoholism treatment. Baltimore, MD: Lippincott Williams & Wilkins; 2003. pp. 282–301.
7. Pettinati HM, Weiss RD, Miller WR, Donovan D, Ernst DB, Rounsaville BJ. COMBINE Monograph Series, Volume 2. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence (DHHS Publication No. 04-5289) Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2004.
8. Lee YK, Park SW, Kim YK, Kim DJ, Jeong J, Myrick H, et al. Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system. Alcohol Alcohol. 2005;40:297–301. [PubMed]
9. Hemby SE, Johnson BA, Dworkin SI. Neurobiological basis of drug reinforcement. In: Johnson BA, Roache JD, editors. Drug addiction and its treatment: nexus of neuroscience and behavior. Philadelphia: Lippincott-Raven; 1997. pp. 137–69.
10. Gysling K, Wang RY. Morphine-induced activation of A10 dopamine neurons in the rat. Brain Res. 1983;277:119–27. [PubMed] 11. Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 1992;12:483–8. [PubMed] 12. Matthews RT, German DC. Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience. 1984;11:617–25. [PubMed] 13. Gianoulakis C. Alcohol-seeking behavior. The roles of the hypothalamic-pituitary-adrenal axis and the endogenous opioid system. Alcohol Health Res World. 1998;22:202–10. [PubMed] 14. Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology. 2000;149:327–44. [PubMed] 15. Krystal JH, Madonick S, Perry E, Gueorguieva R, Brush L, Wray Y, et al. Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism. Neuropsychopharmacology. 2006;31:1793–800. [PubMed] 16. Foster KL, McKay PF, Seyoum R, Milbourne D, Yin W, Sarma PV, et al. GABA(A) and opioid receptors of the central nucleus of the amygdala selectively regulate ethanol-maintained behaviors. Neuropsychopharmacology. 2004;29:269–84. [PubMed] 17. Matsuzawa S, Suzuki T, Misawa M, Nagase H. Roles of 5-HT3 and opioid receptors in the ethanol-induced place preference in rats exposed to conditioned fear stress. Life Sci. 1999;64:PL241–PL9. [PubMed] 18. Manzanares J, Ortiz S, Oliva JM, Perez-Rial S, Palomo T. Interactions between cannabinoid and opioid receptor systems in the mediation of ethanol effects. Alcohol Alcohol. 2005;40:25–34. [PubMed] 19. Resch GE, Shridharani S, Millington WR, Garris DR, Simpson CW. Glycyl-glutamine in nucleus accumbens reduces ethanol intake in alcohol preferring (P) rats. Brain Res. 2005;1058:73–81. [PubMed] 20. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994;45:330–4. [PubMed] 21. Roberts AJ, McDonald JS, Heyser CJ, Kieffer BL, Matthes HW, Koob GF, et al. Mu-opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther. 2000;293:1002–8. [PubMed] 22. Olive MF, Koenig HN, Nannini MA, Hodge CW. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. J Neurosci. 2001;21(RC184):1–5. [PubMed] 23. Marinelli PW, Quirion R, Gianoulakis C. A microdialysis profile of beta-endorphin and catecholamines in the rat nucleus accumbens following alcohol administration. Psychopharmacology. 2003;169:60–7. [PubMed] 24. Marinelli PW, Quirion R, Gianoulakis C. An in vivo profile of beta-endorphin release in the arcuate nucleus and nucleus accumbens following exposure to stress or alcohol. Neuroscience. 2004;127:777–84. [PubMed] 25. Zalewska-Kaszubska J, Gorska D, Dyr W, Czarnecka E. Effect of acute administration of ethanol on beta-endorphin plasma level in ethanol preferring and non-preferring rats chronically treated with naltrexone. Pharmacol Biochem Behav. 2006;85:155–9. [PubMed] 26. Altshuler HL, Phillips PE, Feinhandler DA. Alteration of ethanol self-administration by naltrexone. Life Sci. 1980;26:679–88. [PubMed] 27. Samson HH, Doyle TF. Oral ethanol self-administration in the rat: effect of naloxone. Pharmacol Biochem Behav. 1985;22:91–9. [PubMed] 28. Froehlich JC, Zweifel M, Harts J, Lumeng L, Li TK. Importance of delta opioid receptors in maintaining high alcohol drinking. Psychopharmacology. 1991;103:467–72. [PubMed] 29. De Witte P. Naloxone reduces alcohol intake in a free-choice procedure even when both drinking bottles contain saccharin sodium or quinine substances. Neuropsychobiology. 1984;12:73–7. [PubMed] 30. Froehlich JC, Harts J, Lumeng L, Li TK. Naloxone attenuation of voluntary alcohol consumption. Alcohol Alcohol. 1987;(suppl 1):333–7. [PubMed] 31. Froehlich JC, Harts J, Lumeng L, Li TK. Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Behav. 1990;35:385–90. [PubMed] 32. van Ree JM, Kornet M, Goosen C. Neuropeptides and alcohol addiction in monkeys. EXS. 1994;71:165–74. [PubMed] 33. Le AD, Poulos CX, Quan B, Chou S. The effects of selective blockade of delta and mu opiate receptors on ethanol consumption by C57B1/6 mice in a restricted access paradigm. Brain Res. 1993;630:330–2. [PubMed] 34. Volpicelli JR, Davis MA, Olgin JE. Naltrexone blocks the post-shock increase of ethanol consumption. Life Sci. 1986;38:841–7. [PubMed] 35. Heyser CJ, Moc K, Koob GF. Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. Neuropsychopharmacology. 2003;28:1463–71. [PubMed] 36. Kamdar NK, Miller SA, Syed YM, Bhayana R, Gupta T, Rhodes JS. Acute effects of naltrexone and GBR 12909 on ethanol drinking-in-the-dark in C57BL/6J mice. Psychopharmacology. 2007;192:207–17. [PubMed] 37. Ross D, Hartmann RJ, Geller I. Ethanol preference in the hamster: effects of morphine sulfate and naltrexone, a long-acting morphine antagonist. Proc West Pharmacol Soc. 1976;19:326–30. [PubMed] 38. Berman RF, Lee JA, Olson KL, Goldman MS. Effects of naloxone on ethanol dependence in rats. Drug Alcohol Depend. 1984;13:245–54. [PubMed] 39. Juarez J, Eliana Bde T. Alcohol consumption is enhanced after naltrexone treatment. Alcohol Clin Exp Res. 2007;31:260–4. [PubMed] 40. Williams KL, Broadbear JH, Woods JH. Noncontingent and response-contingent intravenous ethanol attenuates the effect of naltrexone on hypothalamic-pituitary-adrenal activity in rhesus monkeys. Alcohol Clin Exp Res. 2004;28:566–71. [PubMed] 41. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology. 1997;129:99–111. [PubMed] 42. Gianoulakis C, de Waele JP, Thavundayil J. Implication of the endogenous opioid system in excessive ethanol consumption. Alcohol. 1996;13:19–23. [PubMed] 43. Grisel JE, Mogil JS, Grahame NJ, Rubinstein M, Belknap JK, Crabbe JC, et al. Ethanol oral self-administration is increased in mutant mice with decreased beta-endorphin expression. Brain Res. 1999;835:62–7. [PubMed] 44. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry. 1994;151:1463–7. [PubMed] 45. Davidson D, Swift R, Fitz E. Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res. 1996;20:732–9. [PubMed] 46. Doty P, de Wit H. Effects of naltrexone pretreatment on the subjective and performance effects of ethanol in social drinkers. Behav Pharmacol. 1995;6:386–94. [PubMed] 47. King AC, Volpicelli JR, Frazer A, O’Brien CP. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology. 1997;129:15–22. [PubMed] 48. Krishnan-Sarin S, Krystal JH, Shi J, Pittman B, O’Malley SS. Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biol Psychiatry. 2007;62:694–7. [PubMed] 49. McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda RJ. Genetic moderators of naltrexone’s effects on alcohol cue reactivity. Alcohol Clin Exp Res. 2006;30:1288–96. [PubMed] 50. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28:1546–52. [PubMed] 51. O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881–7. [PubMed] 52. Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876–80. [PubMed] 53. Jaffe AJ, Rounsaville B, Chang G, Schottenfeld RS, Meyer RE, O’Malley SS. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol. 1996;64:1044–53. [PubMed] 54. O’Malley SS, Jaffe AJ, Rode S, Rounsaville BJ. Experience of a “slip” among alcoholics treated with naltrexone or placebo. Am J Psychiatry. 1996;153:281–3. [PubMed] 55. Volpicelli JR, Watson NT, King AC, Sherman CE, O’Brien CP. Effect of naltrexone on alcohol “high” in alcoholics. Am J Psychiatry. 1995;152:613–5. [PubMed] 56. Bouza C, Angeles M, Munoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004;99:811–28. [PubMed] 57. Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2005;1:CD001867. [PubMed] 58. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O’Brien CP. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry. 1997;54:737–42. [PubMed] 59. Litten RZ, Allen J, Fertig J. Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991. Alcohol Clin Exp Res. 1996;20:859–76. [PubMed] 60. Litten RZ, Allen JP. Advances in development of medications for alcoholism treatment. Psychopharmacology. 1998;139:20–33. [PubMed] 61. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry. 1997;54:1130–5. [PubMed] 62. Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence — The COMBINE Study: a randomized controlled trial. JAMA. 2006;295:2003–17. [PubMed] 63. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res. 2007;31:555–63. [PubMed] 64. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998;95:9608–13. [PubMed] 65. Befort K, Filliol D, Décaillot FM, Gavériaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem. 2001;276:3130–7. [PubMed] 66. Beyer A, Koch T, Schröder H, Schulz S, Höllt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem. 2004;89:553–60. [PubMed] 67. Zhang Y, Wang D, Johnson AD, Papp AC, Sadée W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem. 2005;280:32618–24. [PubMed] 68. Gelernter J, Kranzler H, Cubells J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry. 1999;4:476–83. [PubMed] 69. Zhang H, Luo X, Kranzler HR, Lappalainen J, Yang B-Z, Krupitsky E, et al. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet. 2006;15:807–19. [PMC free article] [PubMed] 70. King AC, Schluger J, Gunduz M, Borg L, Perret G, Ho A, et al. Hypothalamic-pituitary-adrenocortical (HPA) axis response and biotransformation of oral naltrexone: preliminary examination of relationship to family history of alcoholism. Neuropsychopharmacology. 2002;26:778–88. [PubMed] 71. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O’Brien CP, et al. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict. 2001;10:258–68. [PubMed] 72. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28:5–24. [PubMed]
73. Lewis DH. Controlled release of bioactive agents from lactide/glycolide polymers. In: Chasin M, Langer R, editors. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker; 1990. pp. 1–41.
74. Johnson BA, Ait-Daoud N, Aubin H-J, van den Brink W, Guzzetta R, Loewy J, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex®) in patients with alcohol dependence. Alcohol Clin Exp Res. 2004;28:1356–61. [PubMed] 75. Garbutt JC, Kranzler HR, O’Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617–25. [PubMed] 76. Kranzler HR, Wesson DR, Billot L. Drug Abuse Sciences Naltrexone Depot Study Group. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004;28:1051–9. [PubMed] 77. Galloway GP, Koch M, Cello R, Smith DE. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial. BMC Psychiatry. 2005;5:18. [PMC free article] [PubMed] 78. Conigrave KM, Degenhardt LJ, Whitfield JB, Saunders JB, Helander A, Tabakoff B, et al. CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA collaborative project. Alcohol Clin Exp Res. 2002;26:332–9. [PubMed] 79. Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res. 1998;22:1074–9. [PubMed]
80. Alim TN, Tai B, Chiang CN, Green T, Rosse RB, Lindquist T, et al. Tolerability study of a depot form of naltrexone substance abusers [abstract] In: Harris LS, editor. Problems of Drug Dependence 1994: Proceedings of the 56th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., Volume II. NIDA Res Monogr. Vol. 153. 1995. p. 253.
81. Heishman SJ, Francis-Wood A, Keenan RM, Chiang CN, Terrill JB, Tai B, et al. Safety and pharmacokinetics of a new formulation of naltrexone [abstract] In: Harris LS, editor. Problems of Drug Dependence 1993: Proceedings of the 55th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., Volume II. NIDA Res Monogr. Vol. 141. 1994. p. 82.
82. Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology. 2002;159:351–60. [PubMed]
83. Zieglgansberger W, Hauser C, Wetzel C, Putzke J, Siggins GR, Spanagel R. Actions of acamprosate on neurons of the central nervous system. In: Soyka M, editor. Acamprosate in relapse prevention of alcoholism. Berlin: Springer; 1996. pp. 65–70.
84. De Witte P, Bachteler D, Spanagel R. Acamprosate: preclinical data. In: Spanagel R, Mann KF, editors. Drugs for relapse prevention of alcoholism. Basel, Switzerland: Birkhäuser Verlag; 2005. pp. 73–83.
85. De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs. 2005;19:517–37. [PubMed] 86. Harris BR, Prendergast MA, Gibson DA, Rogers DT, Blanchard JA, Holley RC, et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res. 2002;26:1779–93. [PubMed] 87. Boismare F, Daoust M, Moore N, Saligaut C, Lhuintre JP, Chretien P, et al. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav. 1984;21:787–9. [PubMed] 88. Le Magnen J, Tran G, Durlach J. Lack of effects of Ca-acetyl homotaurinate on chronic and acute toxicities of ethanol in rats. Alcohol. 1987;4:103–8. [PubMed] 89. Czachowski CL, Legg BH, Samson HH. Effects of acamprosate on ethanol-seeking and self-administration in the rat. Alcohol Clin Exp Res. 2001;25:344–50. [PubMed] 90. Escher T, Mittleman G. Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone. Addict Biol. 2006;11:55–63. [PubMed] 91. Dahchour A, De Witte P, Bolo N, Nédélec JF, Muzet M, Durbin P, et al. Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res. 1998;82:107–14. [PubMed] 92. Rossetti ZL, Carboni S. Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum. Eur J Pharmacol. 1995;283:177–83. [PubMed] 93. Gewiss M, Heidbreder C, Opsomer L, Durbin P, De Witte P. Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol. 1991;26:129–37. [PubMed] 94. Spanagel R, Putzke J, Stefferl A, Schobitz B, Zieglgansberger W. Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur J Pharmacol. 1996;305:45–50. [PubMed] 95. Bolo N, Nédélec JF, Muzet M, De Witte P, Dahchour A, Durbin P, et al. Central effects of acamprosate: part 2. Acamprosate modifies the brain in-vivo proton magnetic resonance spectrum in healthy young male volunteers. Psychiatry Res. 1998;82:115–27. [PubMed] 96. Putzke J, Spanagel R, Tolle TR, Zieglgansberger W. The anti-craving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal. Eur J Pharmacol. 1996;317:39–48. [PubMed] 97. Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction. 1995;90:1179–88. [PubMed] 98. Krystal JH, Petrakis IL, Krupitsky E, Schutz C, Trevisan L, D’Souza DC. NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy. Ann N Y Acad Sci. 2003;1003:176–84. [PubMed] 99. Sinclair JD, Li TK. Long and short alcohol deprivation: effects on AA and P alcohol-preferring rats. Alcohol. 1989;6:505–9. [PubMed] 100. Spanagel R, Herz A, Shippenberg TS. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A. 1992;89:2046–50. [PubMed] 101. Spanagel R, Holter SM, Allingham K, Landgraf R, Zieglgansberger W. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol. 1996;305:39–44. [PubMed] 102. Wolffgramm J, Heyne A. From controlled drug intake to loss of control: the irreversible development of drug addiction in the rat. Behav Brain Res. 1995;70:77–94. [PubMed] 103. Spanagel R, Zieglgansberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci. 1997;18:54–9. [PubMed] 104. Mason BJ, Goodman AM, Dixon RM, Hameed MH, Hulot T, Wesnes K, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology. 2002;27:596–606. [PubMed] 105. Johnson BA, O’Malley SS, Ciraulo DA, Roache JD, Chambers RA, Sarid-Segal O, et al. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol. 2003;23:281–93. [PubMed] 106. Ooteman W, Koeter MW, Verheul R, Schippers GM, van den Brink W. The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. Eur Neuropsychopharmacol. 2007;17:558–66. [PubMed] 107. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res. 2004;28:51–63. [PubMed] 108. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25:1335–41. [PubMed] 109. Chick J, Lehert P, Landron F. Plinius Maior Society. Does acamprosate improve reduction of drinking as well as aiding abstinence? J Psychopharmacol. 2003;17:397–402. [PubMed] 110. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res. 2006;40:383–93. [PubMed] 111. Verheul R, Lehert P, Geerlings PJ, Koeter MW, van den Brink W. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology. 2005;178:167–73. [PubMed] 112. Nagy J. Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism? IDrugs. 2004;7:339–50. [PubMed] 113. Kotlinska J, Bochenski M, Danysz W. N-methyl-D-aspartate and group I metabotropic glutamate receptors are involved in the expression of ethanol-induced sensitization in mice. Behav Pharmacol. 2006;17:1–8. [PubMed] 114. Bisaga A, Evans SM. Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology. 2004;172:16–24. [PubMed] 115. Krupitsky EM, Neznanova O, Masalov D, Burakov AM, Didenko T, Romanova T, et al. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry. 2007;164:519–23. [PubMed] 116. Evans SM, Levin FR, Brooks DJ, Garawi F. A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res. 2007;31:775–82. [PubMed] 117. Gibbs JW, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia. 2000;41(suppl 1):S10–6. [PubMed] 118. Skradski S, White HS. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia. 2000;41(suppl 1):S45–7. [PubMed] 119. Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci. 2003;23:7069–74. [PubMed] 120. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 1997;28:167–79. [PubMed] 121. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia. 2000;41(suppl 1):S17–20. [PubMed] 122. Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia. 2000;41(suppl 1):S52–60. [PubMed] 123. Taverna S, Sancini G, Mantegazza M, Franceschetti S, Avanzini G. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther. 1999;288:960–8. [PubMed] 124. Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Solis JM. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology. 2002;42:210–20. [PubMed] 125. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia. 2000;41(suppl 1):S35–9. [PubMed] 126. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(suppl 1):S3–9. [PubMed] 127. Johnson BA. Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study. Alcohol Clin Exp Res. 2004;28:1137–44. [PubMed] 128. Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs. 2005;19:873–96. [PubMed] 129. Gabriel KI, Cunningham CL. Effects of topiramate on ethanol and saccharin consumption and preferences in C57BL/6J mice. Alcohol Clin Exp Res. 2005;29:75–80. [PubMed] 130. Nguyen SA, Malcolm R, Middaugh LD. Topiramate reduces ethanol consumption by C57BL/6 mice. Synapse. 2007;61:150–6. [PubMed]
131. Lynch WJ, Johnson BA. Effects of topiramate on alcohol consumption in the rat. Alcohol Clin Exp Res. 2007;31(s2):261A. abstract.
132. Farook JM, Morrell DJ, Lewis B, Littleton JM, Barron S. Topiramate (Topamax®) reduces conditioned abstinence behaviours and handling-induced convulsions (HIC) after chronic administration of alcohol in Swiss-Webster mice. Alcohol Alcohol. in press. [PubMed] 133. Johnson BA, Mann K, Willenbring ML, Litten RZ, Swift RM, Lesch OM, et al. Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry. Alcohol Clin Exp Res. 2005;29:1528–40. [PubMed] 134. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677–85. [PubMed] 135. Ma JZ, Ait-Daoud N, Johnson BA. Topiramate reduces the harm of excessive drinking: implications for public health and primary care. Addiction. 2006;101:1561–8. [PubMed]
136. Miranda R, Monti P, Swift R, MacKillop J, Tidey J, Gwaltney C, et al. Effects of topiramate on alcohol cue reactivity and the subjective effects of drinking. Poster presentation at the 45th Annual Meeting of the American College of Neuropsychopharmacology; Hollywood, Florida. December 6, 2006.
137. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Topiramate for the treatment of alcohol dependence: results of a multi-site trial. New Research poster presentation at the 160th Annual Meeting of the American Psychiatric Association; San Diego, California. May 22, 2007.
138. Johnson & Johnson Pharmaceutical Research & Development. Investigator’s Brochure: Topiramate (RWJ-17021-000) 10. Dec, 2005.
139. Biton V, Edwards KR, Montouris GD, Sackellares JC, Harden CL, Kamin M, et al. Topiramate titration and tolerability. Ann Pharmacother. 2001;35:173–9. [PubMed] 140. Myers RD, Veale WL. Alcohol preference in the rat: reduction following depletion of brain serotonin. Science. 1968;160:1469–71. [PubMed] 141. Nachman M, Lester D, Le Magnen J. Alcohol aversion in the rat: behavioral assessment of noxious drug effects. Science. 1970;168:1244–6. [PubMed] 142. Daoust M, Chretien P, Moore N, Saligaut C, Lhuintre JP, Boismare F. Isolation and striatal (3H) serotonin uptake: role in the voluntary intake of ethanol by rats. Pharmacol Biochem Behav. 1985;22:205–8. [PubMed] 143. Geller I. Effects of para-chlorophenylalanine and 5-hydroxytryptophan on alcohol intake in the rat. Pharmacol Biochem Behav. 1973;1:361–5. [PubMed] 144. Gill K, Amit Z, Koe BK. Treatment with sertraline, a new serotonin uptake inhibitor, reduces voluntary ethanol consumption in rats. Alcohol. 1988;5:349–54. [PubMed] 145. Gill K, Filion Y, Amit Z. A further examination of the effects of sertraline on voluntary ethanol consumption. Alcohol. 1988;5:355–8. [PubMed]
146. Zabik JE, Binkerd K, Roache JD. Serotonin and ethanol aversion in the rat. In: Naranjo CA, Sellers EM, editors. Research advances in new psychopharmacological treatments for alcoholism: proceedings of the symposium; Toronto. 4-5 October 1984; Amsterdam: Excerpta Medica; 1985. pp. 87–105.
147. McBride WJ, Murphy JM, Lumeng L, Li TK. Serotonin and ethanol preference. Recent Dev Alcohol. 1989;7:187–209. [PubMed] 148. Boyce-Rustay JM, Wiedholz LM, Millstein RA, Carroll J, Murphy DL, Daws LC, et al. Ethanol-related behaviors in serotonin transporter knockout mice. Alcohol Clin Exp Res. 2006;30:1957–65. [PubMed]
149. Blundell JE, Latham CJ. Behavioural pharmacology of feeding. In: Silverstone T, editor. Drugs and appetite. London: Academic Press; 1982. pp. 41–80.
150. Blundell JE. Serotonin and appetite. Neuropharmacology. 1984;23:1537–51. [PubMed] 151. Maurel S, De Vry J, Schreiber R. Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats. Alcohol. 1999;17:195–201. [PubMed] 152. Gill K, Amit Z. Serotonin uptake blockers and voluntary alcohol consumption. A review of recent studies. Recent Dev Alcohol. 1989;7:225–48. [PubMed] 153. Gottfries CG. Influence of depression and antidepressants on weight. Acta Psychiatr Scand Suppl. 1981;290:353–6. [PubMed] 154. Simpson RJ, Lawton DJ, Watt MH, Tiplady B. Effect of zimelidine, a new antidepressant, on appetite and body weight. Br J Clin Pharmacol. 1981;11:96–8. [PubMed] 155. Leander JD. Fluoxetine suppresses palatability-induced ingestion. Psychopharmacology. 1987;91:285–7. [PubMed]
156. Stellar JR, Stellar E. The neurobiology of motivation and reward. New York: Springer-Verlag; 1985.
157. Wurtman JJ, Wurtman RJ. Fenfluramine and fluoxetine spare protein consumption while suppressing caloric intake by rats. Science. 1977;198:1178–80. [PubMed] 158. Wurtman JJ, Wurtman RJ. Drugs that enhance central serotoninergic transmission diminish elective carbohydrate consumption by rats. Life Sci. 1979;24:895–903. [PubMed]
159. Li ET, Anderson GH. 5-Hydroxytryptamine control of meal to meal composition chosen by rats. Fed Proc. 1983;42:542–8.
160. Heisler LK, Kanarek RB, Gerstein A. Fluoxetine decreases fat and protein intakes but not carbohydrate intake in male rats. Pharmacol Biochem Behav. 1997;58:767–73. [PubMed] 161. Heisler LK, Kanarek RB, Homoleski B. Reduction of fat and protein intakes but not carbohydrate intake following acute and chronic fluoxetine in female rats. Pharmacol Biochem Behav. 1999;63:377–85. [PubMed]
162. Smith GP. The physiology of the meal. In: Silverstone T, editor. Drugs and appetite. London; Academic Press: 1982.
163. Fantino M. Role of sensory input in the control of food intake. J Auton Nerv Syst. 1984;10:347–58. [PubMed] 164. Wise RA, Raptis L. Effects of pre-feeding on food-approach latency and food consumption speed in food deprived rats. Physiol Behav. 1985;35:961–3. [PubMed] 165. Haraguchi M, Samson HH, Tolliver GA. Reduction in oral ethanol self-administration in the rat by the 5-HT uptake blocker fluoxetine. Pharmacol Biochem Behav. 1990;35:259–62. [PubMed] 166. Gulley JM, McNamara C, Barbera TJ, Ritz MC, George FR. Selective serotonin reuptake inhibitors: effects of chronic treatment on ethanol-reinforced behavior in mice. Alcohol. 1995;12:177–81. [PubMed] 167. Murphy JM, Waller MB, Gatto GJ, McBride WJ, Lumeng L, Li TK. Effects of fluoxetine on the intragastric self-administration of ethanol in the alcohol preferring P line of rats. Alcohol. 1988;5:283–6. [PubMed] 168. Naranjo CA, Sellers EM, Roach CA, Woodley DV, Sanchez-Craig M, Sykora K. Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. Clin Pharmacol Ther. 1984;35:374–81. [PubMed] 169. Naranjo CA, Sellers EM, Sullivan JT, Woodley DV, Kadlec K, Sykora K. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther. 1987;41:266–74. [PubMed] 170. Naranjo CA, Sellers EM. Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers. Recent Dev Alcohol. 1989;7:255–66. [PubMed] 171. Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther. 1990;47:490–8. [PubMed] 172. Naranjo CA, Poulos CX, Bremner KE, Lanctot KL. Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther. 1992;51:729–39. [PubMed] 173. Gorelick DA, Paredes A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res. 1992;16:261–5. [PubMed] 174. Naranjo CA, Bremner KE, Lanctot KL. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction. 1995;90:87–99. [PubMed] 175. Kabel DI, Petty F. A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res. 1996;20:780–4. [PubMed] 176. Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry. 1995;152:391–7. [PubMed] 177. Johnson BA. Serotonergic agents and alcoholism treatment: rebirth of the subtype concept—an hypothesis. Alcohol Clin Exp Res. 2000;24:1597–601. [PubMed] 178. Cloninger CR. Neurogenetic adaptive mechanisms in alcoholism. Science. 1987;236:410–6. [PubMed] 179. Buydens-Branchey L, Branchey MH, Noumair D. Age of alcoholism onset. I. Relationship to psychopathology. Arch Gen Psychiatry. 1989;46:225–30. [PubMed] 180. Linnoila M, Virkkunen M. Biologic correlates of suicidal risk and aggressive behavioral traits. J Clin Psychopharmacol. 1992;12(2 suppl):19S–20S. [PubMed] 181. Linnoila M, De Jong J, Virkkunen M. Family history of alcoholism in violent offenders and impulsive fire setters. Arch Gen Psychiatry. 1989;46:613–6. [PubMed] 182. Kranzler HR, Burleson JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996;20:1534–41. [PubMed] 183. Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res. 2000;24:1041–9. [PubMed] 184. Dundon W, Lynch KG, Pettinati HM, Lipkin C. Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. Alcohol Clin Exp Res. 2004;28:1065–73. [PMC free article] [PubMed] 185. Chick J, Aschauer H, Hornik K. Investigators’ Group. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend. 2004;74:61–70. [PubMed] 186. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997;54:700–5. [PubMed] 187. Kranzler HR, Mueller T, Cornelius J, Pettinati HM, Moak D, Martin PR, et al. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol. 2006;26:13–20. [PubMed] 188. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA. 1996;275:761–7. [PubMed] 189. McGrath PJ, Nunes EV, Stewart JW, Goldman D, Agosti V, Ocepek-Welikson K, et al. Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry. 1996;53:232–40. [PubMed] 190. Collins DM, Myers RD. Buspirone attenuates volitional alcohol intake in the chronically drinking monkey. Alcohol. 1987;4:49–56. [PubMed] 191. Meert TF. Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. Alcohol Alcohol. 1993;28:157–70. [PubMed] 192. Blier P, de Montigny C. Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse. 1987;1:470–80. [PubMed] 193. Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology. 1989;22(suppl 1):49–59. [PubMed] 194. Malec TS, Malec EA, Dongier M. Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin Exp Res. 1996;20:853–8. [PubMed] 195. Meert TF, Awouters F, Niemegeers CJ, Schellekens KH, Janssen PA. Ritanserin reduces abuse of alcohol, cocaine, and fentanyl in rats. Pharmacopsychiatry. 1991;24:159–63. [PubMed] 196. Myers RD, Lankford M, Bjork A. Selective reduction by the 5-HT antagonist amperozide of alcohol preference induced in rats by systemic cyanamide. Pharmacol Biochem Behav. 1992;43:661–7. [PubMed] 197. Svensson L, Fahlke C, Hard E, Engel JA. Involvement of the serotonergic system in ethanol intake in the rat. Alcohol. 1993;10:219–24. [PubMed] 198. Myers RD, Lankford MF. Suppression of alcohol preference in high alcohol drinking rats: efficacy of amperozide versus naltrexone. Neuropsychopharmacology. 1996;14:139–49. [PubMed] 199. Myers RD, Lankford M. Action of the 5-HT2A antagonist amperozide on alcohol-induced poikilothermia in rats. Pharmacol Biochem Behav. 1998;59:91–5. [PubMed] 200. Biggs TA, Myers RD. Naltrexone and amperozide modify chocolate and saccharin drinking in high alcohol-preferring P rats. Pharmacol Biochem Behav. 1998;60:407–13. [PubMed] 201. Overstreet DH, McArthur RA, Rezvani AH, Post C. Selective inhibition of alcohol intake in diverse alcohol-preferring rat strains by the 5-HT2A antagonists amperozide and FG 5974. Alcohol Clin Exp Res. 1997;21:1448–54. [PubMed] 202. Roberts AJ, McArthur RA, Hull EE, Post C, Koob GF. Effects of amperozide, 8-OH-DPAT, and FG 5974 on operant responding for ethanol. Psychopharmacology. 1998;137:25–32. [PubMed] 203. Lankford MF, Bjork AK, Myers RD. Differential efficacy of serotonergic drugs FG5974, FG5893, and amperozide in reducing alcohol drinking in P rats. Alcohol. 1996;13:399–404. [PubMed] 204. Ugedo L, Grenhoff J, Svensson TH. Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology. 1989;98:45–50. [PubMed] 205. Johnson BA, Jasinski DR, Galloway GP, Kranzler H, Weinreib R, Anton RF, et al. Ritanserin in the treatment of alcohol dependence—a multi-center clinical trial. Psychopharmacology. 1996;128:206–15. [PubMed] 206. Wiesbeck GA, Weijers HG, Chick J, Naranjo CA, Boening J. Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group. Alcohol Clin Exp Res. 1999;23:230–5. [PubMed] 207. Lovinger DM, White G. Ethanol potentiation of 5-hydroxytryptamine3 receptor-mediated ion current in neuroblastoma cells and isolated adult mammalian neurons. Mol Pharmacol. 1991;40:263–70. [PubMed] 208. Zhou Q, Lovinger DM. Pharmacologic characteristics of potentiation of 5-HT3 receptors by alcohols and diethyl ether in NCB-20 neuroblastoma cells. J Pharmacol Exp Ther. 1996;278:732–40. [PubMed] 209. Lovinger DM, Zhou Q. Alcohols potentiate ion current mediated by recombinant 5-HT3RA receptors expressed in a mammalian cell line. Neuropharmacology. 1994;33:1567–72. [PubMed] 210. Lovinger DM. Inhibition of 5-HT3 receptor-mediated ion current by divalent metal cations in NCB-20 neuroblastoma cells. J Neurophysiol. 1991;66:1329–37. [PubMed] 211. Lovinger DM. Ethanol potentiates ion current mediated by 5-HT3 receptors on neuroblastoma cells and isolated neurons. Alcohol Alcohol Suppl. 1991;1:181–5. [PubMed] 212. Lovinger DM. 5-HT3 receptors and the neural actions of alcohols: an increasingly exciting topic. Neurochem Int. 1999;35:125–30. [PubMed] 213. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38:1083–152. [PubMed]
214. Johnson BA, Cowen PJ. Alcohol-induced reinforcement: dopamine and 5-HT3 receptor interactions in animals and humans. Drug Dev Res. 1993;30:153–69.
215. Koob GF. Neural mechanisms of drug reinforcement. Ann N Y Acad Sci. 1992;654:171–91. [PubMed] 216. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev. 1987;94:469–92. [PubMed] 217. Bradbury AJ, Costall B, Domeney AM, Naylor RJ. Laterality of dopamine function and neuroleptic action in the amygdala in the rat. Neuropharmacology. 1985;24:1163–70. [PubMed] 218. Hagan RM, Jones BJ, Jordan CC, Tyers MB. Effect of 5-HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat. Br J Pharmacol. 1990;99:227–32. [PubMed] 219. Eison AS, Iversen SD, Sandberg BE, Watson SP, Hanley MR, Iversen LL. Substance P analog, DiMe-C7: evidence for stability in rat brain and prolonged central actions. Science. 1982;215:188–90. [PubMed] 220. Costall B, Domeney AM, Naylor RJ, Tyers MB. Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol. 1987;92:881–94. [PubMed] 221. Hodge CW, Samson HH, Lewis RS, Erickson HL. Specific decreases in ethanol- but not water-reinforced responding produced by the 5-HT3 antagonist ICS 205-930. Alcohol. 1993;10:191–6. [PubMed] 222. Fadda F, Garau B, Marchei F, Colombo G, Gessa GL. MDL 72222, a selective 5-HT3 receptor antagonist, suppresses voluntary ethanol consumption in alcohol-preferring rats. Alcohol Alcohol. 1991;26:107–10. [PubMed]
223. Rodd-Henricks ZA, McKinzie DL, Li T-K, Crile RS, Murphy JM, McBride WJ. Intracranial self-administration of ethanol into the posterior VTA of Wistar rats is mediated by 5-HT3 receptors. Alcohol Clin Exp Res. 1999;23(suppl 5):49A. abstract.
224. Johnson BA, Campling GM, Griffiths P, Cowen PJ. Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers. Psychopharmacology. 1993;112:142–4. [PubMed] 225. Dyr W, Kostowski W. Evidence that the amygdala is involved in the inhibitory effects of 5-HT3 receptor antagonists on alcohol drinking in rats. Alcohol. 1995;12:387–91. [PubMed] 226. Sellers EM, Higgins GA, Tompkins DM, Romach MK. Serotonin and alcohol drinking. NIDA Res Monogr. 1992;119:141–5. [PubMed] 227. McBride WJ, Li TK. Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents. Crit Rev Neurobiol. 1998;12:339–69. [PubMed] 228. Tomkins DM, Le AD, Sellers EM. Effect of the 5-HT3 antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure. Psychopharmacology. 1995;117:479–85. [PubMed] 229. Beardsley PM, Lopez OT, Gullikson G, Flynn D. Serotonin 5-HT3 antagonists fail to affect ethanol self-administration of rats. Alcohol. 1994;11:389–95. [PubMed] 230. Swift RM, Davidson D, Whelihan W, Kuznetsov O. Ondansetron alters human alcohol intoxication. Biol Psychiatry. 1996;40:514–21. [PubMed] 231. Doty P, Zacny JP, de Wit H. Effects of ondansetron pretreatment on acute responses to ethanol in social drinkers. Behav Pharmacol. 1994;5:461–9. [PubMed] 232. Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res. 1994;18:879–85. [PubMed] 233. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 2000;284:963–71. [PubMed] 234. Kranzler HR, Pierucci-Lagha A, Feinn R, Hernandez-Avila C. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res. 2003;27:1150–5. [PubMed] 235. Russell RN, McBride WJ, Lumeng L, Li TK, Murphy JM. Apomorphine and 7-OH DPAT reduce ethanol intake of P and HAD rats. Alcohol. 1996;13:515–9. [PubMed] 236. Mason GA, Rezvani AH, Grady DR, Garbutt JC. The subchronic effects of the TRH analog TA-0910 and bromocriptine on alcohol preference in alcohol-preferring rats: development of tolerance and cross-tolerance. Alcohol Clin Exp Res. 1994;18:1196–201. [PubMed] 237. Weiss F, Mitchiner M, Bloom FE, Koob GF. Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocriptine, and methysergide. Psychopharmacology. 1990;101:178–86. [PubMed] 238. Dongier M, Vachon L, Schwartz G. Bromocriptine in the treatment of alcohol dependence. Alcohol Clin Exp Res. 1991;15:970–7. [PubMed] 239. Naranjo CA, George SR, Bremner KE. Novel neuropharmacological treatments of alcohol dependence. Clin Neuropharmacol. 1992;15(suppl 1 Pt A):74A–5A. [PubMed] 240. Powell BJ, Campbell JL, Landon JF, Liskow BI, Thomas HM, Nickel EJ, et al. A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders. Alcohol Clin Exp Res. 1995;19:462–8. [PubMed] 241. Colombo G, Agabio R, Carai MA, Lobina C, Pani M, Reali R, et al. Ability of baclofen in reducing alcohol intake and withdrawal severity: I—preclinical evidence. Alcohol Clin Exp Res. 2000;24:58–66. [PubMed] 242. Colombo G, Serra S, Brunetti G, Vacca G, Carai MA, Gessa GL. Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend. 2003;70:105–8. [PubMed] 243. Colombo G, Serra S, Vacca G, Gessa GL, Carai MA. Suppression by baclofen of the stimulation of alcohol intake induced by morphine and WIN 55,212-2 in alcohol-preferring rats. Eur J Pharmacol. 2004;492:189–93. [PubMed] 244. Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G. Ability of baclofen in reducing alcohol craving and intake: II—Preliminary clinical evidence. Alcohol Clin Exp Res. 2000;24:67–71. [PubMed] 245. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002;37:504–8. [PubMed]
246. Ait-Daoud N, Johnson BA. Medications for the treatment of alcoholism. In: Johnson BA, Ruiz P, Galanter M, editors. Handbook of clinical alcoholism treatment. Baltimore, MD: Lippincott Williams & Wilkins; 2003. pp. 119–30.
247. Sidmak Laboratories, Inc. Antabuse [package insert] East Hanover, Nj: Sidmak Laboratories, Inc; 2001.
248. O’Shea B. Disulfiram revisited. Hosp Med. 2000;61:849–51. [PubMed] 249. Petrakis IL, Carroll KM, Nich C, Gordon LT, McCance-Katz EF, Frankforter T, et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction. 2000;95:219–28. [PubMed] 250. Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi J, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry. 2004;61:264–72. [PMC free article] [PubMed] 251. Baker JR, Jatlow P, McCance-Katz EF. Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend. 2007;87:202–9. [PMC free article] [PubMed] 252. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA. 1986;256:1449–55. [PubMed] 253. Anton RF. Pharmacologic approaches to the management of alcoholism. J Clin Psychiatry. 2001;62(suppl 20):11–7. [PubMed] 254. Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006;111:855–76. [PubMed] 255. Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A. 2003;100:1393–8. [PubMed] 256. Caille S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH. Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci. 2007;27:3695–702. [PubMed] 257. Basavarajappa BS, Hungund BL. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells. J Neurochem. 1999;72:522–8. [PubMed] 258. Lallemand F, De Witte P. SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats. Alcohol. 2006;39:125–34. [PubMed] 259. Rodriguez de Fonseca F, Roberts AJ, Bilbao A, Koob GF, Navarro M. Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers. Zhongguo Yao Li Xue Bao. 1999;20:1109–14. [PubMed] 260. Gessa GL, Serra S, Vacca G, Carai MA, Colombo G. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcohol. 2005;40:46–53. [PubMed] 261. Colombo G, Vacca G, Serra S, Carai MA, Gessa GL. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol’s motivational properties in alcohol-preferring rats. Eur J Pharmacol. 2004;498:119–23. [PubMed] 262. Economidou D, Mattioli L, Cifani C, Perfumi M, Massi M, Cuomo V, et al. Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology. 2006;183:394–403. [PubMed] 263. Cippitelli A, Bilbao A, Hansson AC, del Arco I, Sommer W, Heilig M, et al. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur J Neurosci. 2005;21:2243–51. [PubMed] 264. Steffens M, Feuerstein TJ. Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex—involvement of Na(+)/K(+)-ATPase. Neurochem Int. 2004;44:529–38. [PubMed] 265. Moranta D, Esteban S, Garcia-Sevilla JA. Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:516–24. [PubMed] 266. Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, Nomikos GG. The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur J Pharmacol. 2001;426:R3–4. [PubMed] 267. Johnson BA. New weapon to curb smoking: no more excuses to delay treatment. Arch Intern Med. 2006;166:1547–50. [PubMed] 268. Hemby SE, Co C, Koves TR, Smith JE, Dworkin SI. Differences in extracellular dopamine concentrations in the nucleus accumbens during response-dependent and response-independent cocaine administration in the rat. Psychopharmacology. 1997;133:7–16. [PubMed] 269. Dahchour A, De Witte P. Effects of acamprosate on excitatory amino acids during multiple ethanol withdrawal periods. Alcohol Clin Exp Res. 2003;27:465–70. [PubMed] 270. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60:92–9. [PubMed] 271. Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res. 2000;24:737–42. [PubMed] 272. Ait-Daoud N, Johnson BA, Javors M, Roache JD, Zanca NA. Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker. Alcohol Clin Exp Res. 2001;25:847–9. [PubMed]